MarketCap
Facebook
X
Telegram
Baxter International Cash Flow 2025-2006 | BAX
Brief overview of Baxter International 's cash generation
The comparison covers five available annual reports between 2021 and 2025.
Cash from operations fell 62%, from $2.2 billion to $845 million. The direction warrants attention.
Operating cash flow stayed positive in five out of five periods. The business consistently converted operations into cash.
Operating cash margin decreased to 7.5% from 18.3% initially. The quality of receipts deteriorated.
A $674 million reduction in working capital needs released cash equal to 6% of revenue.
Overall assessment
Baxter International 's cash flows present a mixed picture: positive periods coexist with weak conversion or high funding needs.
Annual Cash Flow Baxter International
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
845 M | 1.02 B | 1.73 B | 1.21 B | 2.22 B | 1.87 B | 2.1 B | 2.02 B | 1.71 B | 1.65 B | 1.77 B | 3.22 B | 3.2 B | 3.11 B | 2.82 B | 3 B | 2.91 B | 2.52 B | 2.3 B | - |
Depreciation & Amortization |
981 M | 997 M | 984 M | 1.07 B | 867 M | 823 M | 789 M | 771 M | 750 M | 800 M | 759 M | 792 M | 635 M | 712 M | 670 M | 685 M | 638 M | 631 M | 581 M | - |
Accounts Payables |
999 M | 968 M | 881 M | 1.11 B | 1.25 B | 1.04 B | 892 M | 1 B | 920 M | 791 M | 716 M | 1.26 B | 1.1 B | 766 M | 795 M | 745 M | 807 M | - | - | - |
Accounts Receivables |
1.7 B | 1.54 B | 1.54 B | 2.34 B | 2.4 B | 1.7 B | 1.8 B | 1.7 B | 1.79 B | 1.69 B | 1.73 B | 2.8 B | 2.91 B | 2.42 B | 2.42 B | 2.26 B | 2.3 B | 1.98 B | - | - |
Total Inventories |
2.23 B | 2.05 B | 1.92 B | 2.68 B | 2.45 B | 1.92 B | 1.65 B | 1.65 B | 1.48 B | 1.43 B | 1.6 B | 3.56 B | 3.5 B | 2.8 B | 2.63 B | 2.37 B | 2.56 B | 2.36 B | - | - |
All numbers in USD currency
Quarterly Cash Flow Baxter International
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q3 | 2009-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
498 M | 213 M | - | - | -193 M | - | - | 163 M | - | - | 479 M | - | 772 M | - | 208 M | - | 1.53 B | - | 377 M | - | 1.16 B | 646 M | 272 M | - | 1.28 B | 574 M | 128 M | - | 1.31 B | 852 M | 430 M | - | 1.32 B | 718 M | 189 M | - | 941 M | 409 M | -333 M | - | 1.05 B | 792 M | 96 M | - | 2.07 B | 1.16 B | 559 M | - | 2.12 B | 1.15 B | 386 M | - | 2.16 B | 1.41 B | 446 M | - | 1.92 B | 1 B | 371 M | 2.07 B | 1.06 B | 279 M | 1.92 B | 1.05 B |
Depreciation & Amortization |
476 M | 237 M | 90 M | 106 M | 247 M | 95 M | 73 M | 271 M | 147 M | 157 M | 313 M | - | 168 M | 193 M | 380 M | - | 645 M | 67 M | 217 M | - | 610 M | 401 M | 199 M | - | 580 M | 385 M | 192 M | - | 586 M | 387 M | 190 M | - | 562 M | 378 M | 194 M | - | 599 M | 395 M | 189 M | - | 593 M | 377 M | 187 M | - | 592 M | 489 M | 236 M | - | 573 M | 366 M | 183 M | - | 534 M | 355 M | 175 M | - | 503 M | 327 M | 158 M | 506 M | 335 M | 166 M | 466 M | 302 M |
Accounts Payables |
1.03 B | 1.09 B | 953 M | 995 M | 963 M | 841 M | 1.25 B | 1.33 B | 1.25 B | 1.24 B | 1.29 B | 1.11 B | 1.23 B | - | 1.22 B | 1.25 B | 999 M | 1 B | 1.02 B | 1.04 B | 1.04 B | 1.04 B | 1.04 B | 892 M | - | - | - | 998 M | - | - | - | 920 M | - | - | - | 791 M | - | - | - | 716 M | - | - | - | 677 M | - | - | - | 1.1 B | - | - | - | 766 M | - | - | - | 795 M | - | - | - | - | - | - | - | - |
Accounts Receivables |
1.63 B | 1.54 B | 1.64 B | 1.62 B | 1.49 B | 1.54 B | 2.37 B | 2.26 B | 2.28 B | 2.27 B | 2.3 B | 2.34 B | 2.3 B | - | 2.3 B | 2.4 B | 1.8 B | 1.8 B | 1.6 B | 1.7 B | 1.7 B | 1.7 B | 1.7 B | 1.8 B | 1.8 B | 1.8 B | 1.8 B | 1.8 B | 1.8 B | 1.7 B | 1.7 B | 1.7 B | 1.7 B | 1.7 B | 1.7 B | 1.69 B | 1.69 B | 1.69 B | 1.69 B | 1.73 B | 1.73 B | 1.73 B | 1.73 B | 1.88 B | 1.88 B | 2.8 B | 2.8 B | 2.91 B | 2.91 B | 2.91 B | 2.91 B | 2.42 B | 2.42 B | 2.42 B | 2.42 B | 2.42 B | 2.35 B | 2.49 B | 2.4 B | 2.2 B | 2.07 B | 2.25 B | 2.23 B | 2.13 B |
Total Inventories |
2.26 B | 2.32 B | 2.46 B | 2.38 B | 2.17 B | 2.1 B | 2.98 B | 2.99 B | 2.87 B | 2.9 B | 2.92 B | 2.68 B | 2.68 B | - | 2.55 B | 2.45 B | 2.02 B | 2.06 B | 2.02 B | 1.92 B | 1.92 B | 1.92 B | 1.92 B | 1.65 B | 1.65 B | 1.65 B | 1.65 B | 1.67 B | 1.67 B | 1.65 B | 1.65 B | 1.48 B | 1.48 B | 1.48 B | 1.48 B | 1.43 B | 1.43 B | 1.43 B | 1.43 B | 1.6 B | 1.6 B | 1.6 B | 1.6 B | 1.58 B | 1.58 B | 3.56 B | 3.56 B | 3.5 B | 3.5 B | 3.5 B | 3.5 B | 2.8 B | 2.8 B | 2.8 B | 2.8 B | 2.63 B | 2.63 B | 2.63 B | 2.63 B | 2.5 B | 2.38 B | 2.48 B | 2.63 B | 2.5 B |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Baxter International , reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Medical instruments sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
STAAR Surgical Company
STAA
|
$ 24.16 | 2.94 % | $ 1.2 B |  USA |
 |
Stereotaxis
STXS
|
$ 1.3 | 0.36 % | $ 118 M | USA |
 |
Microbot Medical
MBOT
|
$ 1.5 | 4.17 % | $ 68.7 M |  Israel |
 |
Retractable Technologies
RVP
|
$ 0.7 | 1.29 % | $ 21 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 10.99 | 0.48 % | $ 2.19 B | USA |
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M | USA |
 |
Utah Medical Products
UTMD
|
$ 69.16 | 0.55 % | $ 224 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 137.0 | 0.38 % | $ 6.11 B | USA |
 |
West Pharmaceutical Services
WST
|
$ 337.75 | 0.03 % | $ 24.4 B | USA |
 |
Alcon
ALC
|
$ 69.12 | 0.3 % | $ 34.1 B |  Schweiz |
 |
AngioDynamics
ANGO
|
$ 15.22 | 0.13 % | $ 632 M | USA |
 |
AtriCure
ATRC
|
$ 53.73 | 4.29 % | $ 2.57 B | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 179.1 | 0.05 % | $ 51.5 B | USA |
 |
BioLife Solutions
BLFS
|
$ 35.38 | 0.37 % | $ 1.69 B | USA |
 |
The Cooper Companies
COO
|
$ 67.69 | 1.31 % | $ 13.5 B | USA |
 |
electroCore
ECOR
|
$ 9.08 | 1.1 % | $ 77 K | USA |
 |
Glaukos Corporation
GKOS
|
$ 185.04 | 4.27 % | $ 10.6 B | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
Haemonetics Corporation
HAE
|
$ 102.84 | 0.24 % | $ 4.85 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 7.95 | 1.62 % | $ 353 M | USA |
 |
ICU Medical
ICUI
|
$ 160.89 | 0.78 % | $ 3.96 B | USA |
 |
InfuSystem Holdings
INFU
|
$ 11.89 | 0.74 % | $ 246 M | USA |
 |
iRhythm Technologies
IRTC
|
$ 122.24 | 0.77 % | $ 3.91 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 350.16 | 0.28 % | $ 125 B | USA |
 |
Repro Med Systems
KRMD
|
$ 3.17 | 0.93 % | $ 146 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 79.59 | 0.22 % | $ 1.8 B | USA |
 |
Milestone Scientific
MLSS
|
$ 0.44 | 0.52 % | $ 36.1 M | USA |
 |
Merit Medical Systems
MMSI
|
$ 87.38 | 1.16 % | $ 5.17 B | USA |
 |
Nephros
NEPH
|
$ 4.36 | 7.39 % | $ 46.3 M | USA |
 |
Envista Holdings Corporation
NVST
|
$ 26.81 | 0.73 % | $ 4.5 B | USA |
 |
OraSure Technologies
OSUR
|
$ 3.39 | 2.27 % | $ 249 M | USA |
 |
Pro-Dex
PDEX
|
$ 66.41 | 18.88 % | $ 214 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 48.79 | 3.85 % | $ 3.29 B | USA |
 |
ResMed
RMD
|
$ 221.05 | 0.04 % | $ 32.2 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
- | - | $ 28.6 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Masimo Corporation
MASI
|
- | - | $ 9.59 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |
 |
Repligen Corporation
RGEN
|
$ 168.53 | 0.55 % | $ 9.48 M | USA |
 |
STERIS plc
STE
|
$ 218.44 | 0.31 % | $ 21.5 B | USA |